March 5, 2018 / 6:32 AM / in 5 months

BRIEF-Santhera Pharmaceuticals ‍Reports Outcome Of Exploratory Trial With Idebenone In PPMS Conducted At NIH​

March 5 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING Ag :

* ‍REPORTS OUTCOME OF EXPLORATORY TRIAL WITH IDEBENONE IN PPMS CONDUCTED AT NIH​

* SANTHERA - ‍EXPLORATORY PHASE I/II CLINICAL TRIAL CONFIRMS SAFETY PROFILE OF IDEBENONE AT A DOSE OF 2,250 MG DAILY OVER A TREATMENT PERIOD OF TWO YEARS​

* SANTHERA - ‍IN ASSESSING EFFICACY ON DISEASE PROGRESSION, NO DIFFERENCE BETWEEN ACTIVE TREATMENT GROUP AND PLACEBO WAS OBSERVED​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below